Chris Orvig

Dr. Christopher Orvig is a distinguished professor in the Department of Chemistry at the University of British Columbia (UBC), where he holds the Canada Research Chair in Inorganic Chemistry. His research focuses on the development of inorganic radiopharmaceuticals for nuclear medicine, particularly in the areas of theranostic agents, chelating ligands, and radiolabeling techniques. He is also known for his work in the synthesis and characterization of metal complexes, especially those involving lanthanides and actinides, and their applications in imaging and therapy. Dr. Orvig has made significant contributions to the field of radiopharmaceutical chemistry, including the design of bifunctional chelating agents for the targeting of radionuclides to specific biological sites. He has published extensively in high-impact journals and has been recognized for his innovative approaches to solving challenges in nuclear medicine.

Chris Orvig is a Professor of Chemistry and Pharmaceutical Sciences specializing in medicinal inorganic chemistry. His research focuses on the development of metallodrugs for therapeutic applications, including the design of chelators for radiopharmaceuticals, the exploration of vanadium compounds as insulin mimics, and the study of metal ions in disease. His work also addresses the coordination chemistry of vanadium in metallopharmaceuticals and the synthesis of metal complexes for medicinal applications. Orvig's research explores the role of metal ions in biological systems, including the speciation of aluminum and the targeting of tumors with radiometals. His contributions span drug design, metal-based therapies, and the removal of aberrant metal ions in disease.